Carbajal E V, Deedwania P C
Department of Medicine, Veterans Affairs Medical Center, Fresno, California, USA.
Med Clin North Am. 1995 Sep;79(5):1063-84. doi: 10.1016/s0025-7125(16)30020-7.
CAD continues to be the principal cause of mortality in the United States, and the largest group of patients with CAD are those with stable angina. Among this group of patients, the most common manifestation of CAD is presence of transient episodes of myocardial ischemia. The presence of transient ischemia and not the severity of angina has been found to be associated with poor clinical outcome in patients with stable CAD. As part of a global treatment strategy for patients with stable CAD, changes in lifestyle and modification of coronary risk factors should be emphasized as an integral part of treatment. Conventional antianginal therapy is quite effective in controlling anginal attacks. Currently, several drugs and therapeutic strategies are available for the treatment of patients with angina (see Table 5). Nitrates are highly effective antianginal drugs with complex beneficial actions in patients with CAD, but their usefulness is limited by development of tolerance during long-term use. When clinically indicated, the use of nitrates should be supplemented with another longer-acting antianginal drug, such as a beta-blocker or a calcium channel blocker. Based on the available data, beta-blockers, when tolerated, seem to be the most effective antianginal drugs for most patients with stable CAD. Beta-blockers are also the most effective anti-ischemic drugs that reduce the magnitude of myocardial ischemia detected during routine daily activities. Calcium channel blockers are also effective vasodilators and good antianginal drugs. The clinician should become familiar with the different actions that this heterogeneous group of drugs has on the heart and vessels. This knowledge allows the clinician to choose the appropriate combination of different antianginal drugs for patients on an individualized basis. It is also critical to develop the treatment strategy by carefully taking into account other associated medical conditions that are frequently encountered in patients with CAD.
冠心病仍然是美国主要的死亡原因,而冠心病患者中最大的群体是稳定型心绞痛患者。在这组患者中,冠心病最常见的表现是短暂性心肌缺血发作。已发现短暂性缺血的存在而非心绞痛的严重程度与稳定型冠心病患者的不良临床结局相关。作为稳定型冠心病患者全球治疗策略的一部分,应强调生活方式改变和冠状动脉危险因素的控制是治疗不可或缺的一部分。传统抗心绞痛治疗在控制心绞痛发作方面相当有效。目前,有几种药物和治疗策略可用于治疗心绞痛患者(见表5)。硝酸盐类是高效抗心绞痛药物,对冠心病患者有复杂的有益作用,但长期使用会因耐受性的产生而限制其效用。临床有指征时,硝酸盐类药物的使用应辅以另一种长效抗心绞痛药物,如β受体阻滞剂或钙通道阻滞剂。根据现有数据,β受体阻滞剂在大多数稳定型冠心病患者能够耐受的情况下,似乎是最有效的抗心绞痛药物。β受体阻滞剂也是最有效的抗缺血药物,可减少日常活动中检测到的心肌缺血程度。钙通道阻滞剂也是有效的血管扩张剂和良好的抗心绞痛药物。临床医生应熟悉这一类异质性药物对心脏和血管的不同作用。这些知识使临床医生能够根据患者个体情况选择不同抗心绞痛药物的合适组合。在制定治疗策略时,仔细考虑冠心病患者常伴发的其他相关疾病也至关重要。